Snanoudj Renaud, Durrbach Antoine, Gauthier Eric, Adams David, Samuel Didier, Ferlicot Sophie, Bedossa Pierre, Prigent Alain, Bismuth Henri, Charpentier Bernard
Service de Néphrologie, Hémodialyse et Transplantation, Villejuif, France.
Nephrol Dial Transplant. 2004 Jul;19(7):1779-85. doi: 10.1093/ndt/gfh063. Epub 2004 May 18.
Familial amyloid polyneuropathy (FAP) is an autosomal dominant disease caused by a point mutation in the gene encoding transthyretin, which is secreted by the liver. Orthotopic liver transplantation (OLT) has been proposed to prevent disease progression. Little is known about long-term changes in renal function and lesions after OLT.
The renal function of 33 patients with FAP was evaluated (proteinuria, serum creatinine, creatinine clearance) before OLT and over a period of at least 5 years afterwards. A pre-transplantation renal biopsy was performed in 14 patients and a follow-up biopsy in eight patients.
Before transplantation, mean serum creatinine concentration was 86 micromol/l (47-126 micromol/l) and creatinine clearance was 71.9+/-31.6 ml/min/1.73 m(2). Proteinuria was detected in 54% of patients (0.3-4 g/day). Pre-transplant renal biopsies (n = 14) revealed glomerular, tubular and vascular amyloid deposits in 90, 58 and 66% of patients, respectively. Eleven patients (33%) died after OLT. Death occurred most frequently in patients having weight losses >7 kg (P<0.05). After transplantation, 25 patients (76%) suffered acute renal failure but only one required dialysis. One month after transplantation, the mean serum creatinine concentration was 134.1+/-73 micromol/l and remained constant during follow-up. Eight patients underwent a second renal biopsy 2 years after transplantation. No significant changes in deposits or renal toxicity due to calcineurin inhibitors were detected.
Although liver transplantation in FAP does not affect existing renal amyloid deposits, it prevents the progression of renal disease.
家族性淀粉样多神经病(FAP)是一种常染色体显性疾病,由肝脏分泌的转甲状腺素蛋白编码基因的点突变引起。原位肝移植(OLT)已被提议用于预防疾病进展。关于OLT后肾功能和病变的长期变化知之甚少。
对33例FAP患者在OLT前及之后至少5年的时间里评估其肾功能(蛋白尿、血清肌酐、肌酐清除率)。14例患者进行了移植前肾活检,8例患者进行了随访活检。
移植前,平均血清肌酐浓度为86微摩尔/升(47 - 126微摩尔/升),肌酐清除率为71.9±31.6毫升/分钟/1.73平方米。54%的患者检测到蛋白尿(0.3 - 4克/天)。移植前肾活检(n = 14)显示,分别有90%、58%和66%的患者存在肾小球、肾小管和血管淀粉样沉积。11例患者(33%)在OLT后死亡。体重减轻>7千克的患者死亡最为常见(P<0.05)。移植后,25例患者(76%)发生急性肾衰竭,但仅1例需要透析。移植后1个月,平均血清肌酐浓度为134.1±73微摩尔/升,随访期间保持稳定。8例患者在移植后2年进行了第二次肾活检。未检测到由于钙调神经磷酸酶抑制剂导致的沉积物或肾毒性有显著变化。
尽管FAP患者的肝移植不影响现有的肾淀粉样沉积,但可预防肾病进展。